A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides
Phase of Trial: Phase III
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Glabellar lines
- Focus Therapeutic Use
- Sponsors Allergan
- 25 Oct 2016 Status changed from active, no longer recruiting to completed.
- 19 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Sep 2016.
- 28 Jul 2015 Planned End Date changed from 1 Jun 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.